Top

Published in:

01-12-2021 | Breast Cancer | Research article

Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

Published in: Breast Cancer Research | Issue 1/2021

Abstract

Background

The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR).

Methods

In this retrospective evaluation of 105 patients with stage II–III breast cancer, oxy-hemoglobin (ctO₂Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2–3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO₂Hb changes across chemotherapy when corrected for pCR status, age, and BMI.

Results

Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO₂Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2–3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, − 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO₂Hb levels with BMI and age.

Conclusions

This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2–3 weeks of chemotherapy.

Cortazar P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/S0140-6736(13)62422-8.CrossRefPubMed

Bonadonna G, Valagussa P, Brambilla C, Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet. 1993;341(8858):1485. https://doi.org/10.1016/0140-6736(93)90933-8.CrossRefPubMed

Cameron DA, et al. Primary systemic therapy for operable breast cancer - 10-year survival data after chemotherapy and hormone therapy. Br. J. Cancer. 1997;76(8):1099. https://doi.org/10.1038/bjc.1997.514.CrossRefPubMedPubMedCentral

B. J. Tromberg, B. W. Pogue, K. D. Paulsen, A. G. Yodh, D. A. Boas, and A. E. Cerussi, “Assessing the future of diffuse optical imaging technologies for breast cancer management,” Med. Phys., 35, no. 6Part1, pp. 2443–2451, 2008, doi: https://doi.org/10.1118/1.2919078.

Cerussi A, et al. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A. 2007;104(10):4014–9. https://doi.org/10.1073/pnas.0611058104.CrossRefPubMedPubMedCentral

Cong W, Intes X, Wang G. Optical tomographic imaging for breast cancer detection. J Biomed Opt. 2017;22(9):1–6. https://doi.org/10.1117/1.JBO.22.9.096011.CrossRefPubMed

Gunther JE, et al. Dynamic diffuse optical tomography for monitoring neoadjuvant chemotherapy in patients with breast cancer. Radiology. 2018;287(3):778–86. https://doi.org/10.1148/radiol.2018161041.CrossRefPubMedPubMedCentral

Choe R, et al. Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography. J Biomed Opt. 2009;14(2):024020. https://doi.org/10.1117/1.3103325.CrossRefPubMedPubMedCentral

Chance B, Cooper CE, Delpy DT, Reynolds EOR, Arridge SR, Schweiger M. Image reconstruction in optical tomography. Philos Trans R Soc Lond Ser B Biol Sci. 1997;352(1354):717–26. https://doi.org/10.1098/rstb.1997.0054.CrossRef

10.

Azizi L, Zarychta K, Ettori D, Tinet E, Tualle J-M. Ultimate spatial resolution with diffuse optical tomography. Opt Express. 2009;17(14):12132–44. https://doi.org/10.1364/OE.17.012132.CrossRefPubMed

11.

O’Sullivan TD, et al. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res. 2013;15(1):R14. https://doi.org/10.1186/bcr3389.CrossRefPubMedPubMedCentral

12.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005;365(9472):1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0.CrossRef

13.

Shahedi K, Emanuelsson M, Wiklund F, Gronberg H. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer. 2006;106(6):1237–42. https://doi.org/10.1002/cncr.21753.CrossRefPubMed

14.

Lim EA, et al. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;162(3):533–40. https://doi.org/10.1007/s10549-017-4150-7.CrossRefPubMed

15.

Flexman ML, et al. Optical biomarkers for breast cancer derived from dynamic diffuse optical tomography. J Biomed Opt. 2013;18(9):096012. https://doi.org/10.1117/1.JBO.18.9.096012.CrossRefPubMed

16.

Symmans WF, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(28):4414–22. https://doi.org/10.1200/JCO.2007.10.6823.CrossRef

17.

Flexman ML, et al. Digital optical tomography system for dynamic breast imaging. J Biomed Opt. 2011;16(7):076014. https://doi.org/10.1117/1.3599955.CrossRefPubMedPubMedCentral

18.

Kim HK, Flexman M, Yamashiro DJ, Kandel JJ, Hielscher AH. PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer. Biomed Opt Express. 2010;1(3):812–24. https://doi.org/10.1364/BOE.1.000812.CrossRefPubMedPubMedCentral

19.

Cody DD. AAPM/RSNA physics tutorial for residents: topics in CT. RadioGraphics. 2002;22(5):1255–68. https://doi.org/10.1148/radiographics.22.5.g02se041255.CrossRefPubMed

20.

Prokop M, Shin HO, Schanz A, Schaefer-Prokop CM. Use of maximum intensity projections in CT angiography: a basic review. RadioGraphics. 1997;17(2):433–51. https://doi.org/10.1148/radiographics.17.2.9084083.CrossRefPubMed

21.

Breiman L. Random forests. Mach Learn. 2001;45(1):5–32. https://doi.org/10.1023/A:1010933404324.CrossRef

22.

A. Liaw and M. Wiener, “Classification and regression by RandomForest,” Forest 23. 2001;Vol.2/3:18–22. https://www.r-project.org/doc/Rnews/Rnews_2002-3.pdf.

23.

Chen R-C, Dewi C, Huang S-W, Caraka RE. Selecting critical features for data classification based on machine learning methods. J Big Data. 2020;7(1):52. https://doi.org/10.1186/s40537-020-00327-4.CrossRef

24.

Choe R, Durduran T. Diffuse optical monitoring of the neoadjuvant breast cancer therapy. IEEE J Sel Top Quantum Electron Publ IEEE Lasers Electro-Opt Soc. 2012;18(4):1367–86. https://doi.org/10.1109/JSTQE.2011.2177963.CrossRef

25.

Zhou C, et al. Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt. 2007;12(5):051903. https://doi.org/10.1117/1.2798595.CrossRefPubMed

26.

Ueda S, et al. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res. 2012;72(17):4318–28. https://doi.org/10.1158/0008-5472.CAN-12-0056.CrossRefPubMedPubMedCentral

27.

Jiang S, et al. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology. 2009;252(2):551–60. https://doi.org/10.1148/radiol.2522081202.CrossRefPubMedPubMedCentral

28.

Cerussi AE, Tanamai VW, Hsiang D, Butler J, Mehta RS, Tromberg BJ. Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy. Philos Transact A Math Phys Eng Sci. 2011;369(1955):4512–30. https://doi.org/10.1098/rsta.2011.0279.CrossRef

29.

Altoe ML, et al. Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy. Biomed Opt Express. 2019;10(8):4305–15. https://doi.org/10.1364/BOE.10.004305.CrossRefPubMedPubMedCentral

30.

Chen JH, Yu HJ, Hsu C, Mehta RS, Carpenter PM, Su MY. Background parenchymal enhancement of the contralateral normal breast: association with tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Transl Oncol. 2015;8(3):204–9. https://doi.org/10.1016/j.tranon.2015.04.001.CrossRefPubMedPubMedCentral

31.

Preibsch H, et al. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response. Eur Radiol. 2016;26(6):1590–6. https://doi.org/10.1007/s00330-015-4011-x.CrossRefPubMed

32.

You C, et al. Association between background parenchymal enhancement and pathologic complete remission throughout the neoadjuvant chemotherapy in breast cancer patients. Transl Oncol. 2017;10(5):786–92. https://doi.org/10.1016/j.tranon.2017.07.005.CrossRefPubMedPubMedCentral

33.

Oh SJ, Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy. Br J Radiol. 2018;91(1088):20170550. https://doi.org/10.1259/bjr.20170550.CrossRefPubMedPubMedCentral

34.

Leo GD, Trimboli RM, Sella T, Sardanelli F. Optical imaging of the breast: basic principles and clinical applications. Am J Roentgenol. 2017;209(1):230–8. https://doi.org/10.2214/AJR.16.17220.CrossRef

35.

Noh JJ, Maskarinec G, Pagano I, Cheung LW-K, Stanczyk FZ. Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast. 2006;15(1):20–8. https://doi.org/10.1016/j.breast.2005.04.014.CrossRefPubMed

36.

Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer. 2007;121(11):2506–11. https://doi.org/10.1002/ijc.22971.CrossRefPubMed

37.

King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. Eur Radiol. 2012;22(12):2641–7. https://doi.org/10.1007/s00330-012-2553-8.CrossRefPubMed

38.

K. D. Miller, C. J. Sweeney, and G. W. S. Jr, “Redefining the target: chemotherapeutics as antiangiogenics,” J Clin Oncol. 2016, doi: https://doi.org/10.1200/JCO.2001.19.4.1195.

39.

Sala E, Warren R, McCann J, Duffy S, Luben R, Day N. High-risk mammographic parenchymal patterns and anthropometric measures: a case-control study. Br J Cancer. 1999;81(7):1257–61. https://doi.org/10.1038/sj.bjc.6690838.CrossRefPubMedPubMedCentral

40.

Stone J, Warren RML, Pinney E, Warwick J, Cuzick J. Determinants of percentage and area measures of mammographic density. Am J Epidemiol. 2009;170(12):1571–8. https://doi.org/10.1093/aje/kwp313.CrossRefPubMed

41.

Boyd NF, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Prev Biomark. 2006;15(11):2086–92. https://doi.org/10.1158/1055-9965.EPI-06-0345.CrossRef

42.

Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer. 1998;78(9):1233–8.CrossRef

Title: Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography
Publication date: 01-12-2021
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI: https://doi.org/10.1186/s13058-021-01396-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Accelerated aging in normal breast tissue of women with breast cancer

Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Correction to: AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer

Artificial image objects for classification of breast cancer biomarkers with transcriptome sequencing data and convolutional neural network algorithms

Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Keynote webinar | Spotlight on antibody–drug conjugates in cancer